Chardan Reiterates Buy Rating on Arbutus Biopharma (ABUS) Following Moderna Settlement
Tweet Send to a Friend
Chardan analyst Keay Kakae reiterated a Buy rating and $5.00 price target on Arbutus Biopharma (NASDAQ: ABUS) after a global ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
